why choose us

First received: May 26, 2023

Clinical Trial: Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

Study Status: Completed

Recruit Status: RECRUITING

Condition: Alcohol Abuse

Study Type: INTERVENTIONAL


Official Title: Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

Brief Summary: This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of the GLP-1 receptor agonist semaglutide s.c.vs placebo on alcohol consumption in 108 patients diagnosed with alcohol use disorder and comorbid obesity (BMI>30 kg/m2).Patients will be treated for 26 weeks with semaglutide subcutaneously (s.c.) once weekly or placebo.The medication will be provided as a supplement to standardised cognitive behavioural therapy.A subgroup of the patients will have two brain scans…

Read more